following a full submission:
secukinumab (Cosentyx®) is accepted for use within NHSScotland.
Indication under review: treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs.
In a randomised phase III study, secukinumab, compared with placebo, significantly improved symptoms in adults with active non-radiographic axial spondyloarthritis.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
- Medicine name:
- secukinumab (Cosentyx)
- SMC ID:
For the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Date advice published
- 18 January 2021